Overview

A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study

Status:
Completed
Trial end date:
2012-08-27
Target enrollment:
Participant gender:
Summary
Characterization of the safety profile of TR-701 Free Acid (FA) in patients with major cutaneous abscess or cellulitis/erysipelas.
Phase:
Phase 2
Details
Lead Sponsor:
Trius Therapeutics LLC
Collaborator:
Bayer
Treatments:
Tedizolid
Torezolid phosphate